Related Experiment Videos
Prinzmetal's angina during cyclophosphamide therapy.
T Stefenelli1, C C Zielinski, H Mayr
1Department of Cardiology, University of Vienna, Austria.
European Heart Journal
|October 1, 1988
Summary
Cyclophosphamide can cause myocardial ischemia, a heart muscle injury, leading to serious cardiac events. This condition appears to be triggered by coronary artery spasm, a sudden narrowing of the heart
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Cyclophosphamide is a widely used chemotherapeutic agent.
- Cardiac complications associated with chemotherapy are a growing concern.
- Understanding drug-induced cardiotoxicity is crucial for patient safety.
Observation:
- A patient developed myocardial ischemia during cyclophosphamide treatment.
- Electrocardiogram showed ST-segment elevation and T-wave inversion.
- The patient experienced angina pectoris, arrhythmias, and cardiac decompensation.
Findings:
- This is the first reported case of cyclophosphamide-induced myocardial ischemia with specific ECG findings.
- The data suggest a causal link between cyclophosphamide and myocardial ischemia.
- Coronary artery spasm is proposed as the underlying mechanism.
Implications:
- Clinicians should be aware of the potential cardiotoxic effects of cyclophosphamide.
- Early recognition and management of cyclophosphamide-induced cardiotoxicity are essential.
- Further research is needed to elucidate the mechanisms and develop preventive strategies.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:17Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
01:29Angina III: Clinical Manifestations and Assessment
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
01:20Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...